Saniona spins out cancer project in new firm

Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.

The photo does not depict the Scandion Oncology drug.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles